Evaluating the results of MyTEMP, a cluster randomised trial of lower temperature haemodialysis: the end of a cool idea?

Abstract

Globally, the burden of chronic kidney disease is growing at an alarming rate.1 If continued unchecked, almost 5 million people are predicted to require dialysis or a kidney transplant by 2030.2 Haemodialysis is the most common type of treatment for those with kidney failure, and its widespread use has extended the lives of millions of people since successful long-term dialysis was established in the 1960s. However, patients face high rates of cardiovascular disease, an average survival of less than 5 years, a significant symptom burden, and negative effects on quality of life.